(Q37486435)

9 April 2018

title

Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats (English)

1 reference

9 April 2018

author name string

Md Shenuarin Bhuiyan

series ordinal

1

1 reference

9 April 2018

Norifumi Shioda

series ordinal

2

1 reference

9 April 2018

Kohji Fukunaga

series ordinal

3

1 reference

9 April 2018

language of work or name

English

0 references

publication date

1 March 2009

1 reference

9 April 2018

Expert Opinion on Therapeutic Targets

published in

1 reference

9 April 2018

volume

13

1 reference

9 April 2018

issue

3

1 reference

9 April 2018

page(s)

275-286

1 reference

9 April 2018

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Bats are natural reservoirs of SARS-like coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

A review of studies on animal reservoirs of the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

21 January 2018

Review of bats and SARS

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

The severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Severe acute respiratory syndrome: identification of the etiological agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

The international response to the outbreak of SARS in 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Potential antivirals and antiviral strategies against SARS coronavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

SARS coronavirus anti-infectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Recent patents on treatment of severe acute respiratory syndrome (SARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

HIV infection is blocked in vitro by recombinant soluble CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Designing CD4 immunoadhesins for AIDS therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

The secret life of ACE2 as a receptor for the SARS virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Angiotensin-converting enzyme 2 protects from severe acute lung failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Passive immunity in prevention and treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

The growth and potential of human antiviral monoclonal antibody therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

A human SARS-CoV neutralizing antibody against epitope on S2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Biologic therapies in rheumatology: lessons learned, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

A welcome burst of human antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Cathepsin L is required for endothelial progenitor cell-induced neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

Severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770802609384

10.1517/13543770802609384

21 January 2018

Identifiers

DOI

1 reference

9 April 2018

PubMed ID

19236150

1 reference

9 April 2018